Davide Di Vece

552 posts

Davide Di Vece

Davide Di Vece

@DavideDiVece

Consultant Cardiologist,Greifswald University Hospital, Germany

Zürich, Schweiz Katılım Temmuz 2010
314 Takip Edilen63 Takipçiler
Davide Di Vece retweetledi
JACC Journals
JACC Journals@JACCJournals·
New 👀insights from the International #Takotsubo (InterTAK) registry! ⬆️ prevalence in ♂️, ⬆️ recognition of midventricular TTS type, & ⬆️ short-term mortality & rates of 🫀 shock in recent years bit.ly/3Xjd7jE #ESCCongress #JACC
JACC Journals tweet media
English
0
25
64
21.3K
Davide Di Vece retweetledi
Davide Capodanno
Davide Capodanno@DFCapodanno·
My take on OCT Trials and where this strategy stands in the current landscape of options for PCI guidance. A thread. 1/17 #CRT2024
Davide Capodanno tweet media
English
4
44
149
26.8K
Davide Di Vece retweetledi
Davide Capodanno
Davide Capodanno@DFCapodanno·
Can we clear arterial atherosclerotic plaques? The ACC.24 Late-Breaking Clinical Trials have been announced. My highlight is the large, phase 3, multicenter, double-blind, randomized, placebo-controlled AEGIS-II trial, a study of CSL112 (apolipoprotein A-I) infusion in patients with acute myocardial infarction. Cholesterol efflux, mediated by apolipoprotein A-I, removes excess cholesterol from atherosclerotic plaque and transports it to the liver for excretion. CSL112 increases cholesterol efflux capacity. A target sample of >18,000 participants will be randomized 1:1 to receive 4 weekly infusions of CSL112 6 g or placebo, initiated prior to or on the day of discharge and within 5 days of first medical contact. The primary outcome is the time to first occurrence of the composite of cardiovascular death, myocardial infarction, or stroke through 90 days. Why do I find it so interesting? AEGIS-II will be the first trial to formally test whether enhancing cholesterol efflux can reduce the rate of recurrent major adverse cardiovascular events. accscientificsession.acc.org/Plan-Your-Prog…
Davide Capodanno tweet media
English
7
78
224
78.6K
Davide Di Vece retweetledi
Daniele De Felice
Daniele De Felice@DanieleBibo·
La prima volta allo Stadium in occasione della foto della squadra. Iniziò tutto da qui. Iniziò dal gruppo. 🤍🖤
Italiano
12
53
490
16.9K
Davide Di Vece retweetledi
Abdulla A. Damluji, MD, PhD
Abdulla A. Damluji, MD, PhD@DrDamluji·
Great #AHA23 so far: @AHA_Research 🥸8 Trials: 8 take aways below Read the read👇👇 1/ATRESIA: Patients with subclinical atrial fibrillation can benefit from apixaban to reduce the risk of stroke and systemic thromboembolism.
Abdulla A. Damluji, MD, PhD tweet media
English
9
189
617
152.6K
Davide Di Vece retweetledi
Dr. AK 🇮🇳
Dr. AK 🇮🇳@docakx·
💥AMIODARONE is a class III antiarrhythmic drug which is widely used in ER for treating arrhythmias. A 🧵 on situations where blind use of amiodarone in emergency can be counterproductive ⚠️⚠️⚠️ With alternate therapeutic options Read on...👇 #MedTwitter #MedEd #MedX
Dr. AK 🇮🇳 tweet media
English
21
475
1.7K
291.5K
Davide Di Vece retweetledi
Matthias Götberg
Matthias Götberg@MGtberg·
I’ve been asked to comment about the recent meta analysis of iFR compared with FFR with regards to outcome. A 🧵
English
4
48
105
55.6K
Davide Di Vece retweetledi
jedicath աǟզǟʀ.ǟɦʍɛɖ
Love 🎢 roller coasters except in the coronaries. #radialfirst 🏒 guide. Wire crossed but couldn’t deliver equipment
English
12
19
83
25.5K
Davide Di Vece retweetledi
Davide Capodanno
Davide Capodanno@DFCapodanno·
At #CVIT2023, I was asked to identify the most influential EuroIntervention papers in 2022 and in the first part of 2023. Since I like them all, I used the Altmetric score to be more objective, and I ordered them from position 15 to 1. A topic dominates clearly: bifurcation PCI.
English
0
29
79
10.4K